22554 Federal Register / Vol. 80, No. 77 / Wednesday, April 22, 2015 / Notices 

the application pursuant to 21 CFR 

1301.43 on or before May 22, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODXL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on January 

8, 2015, Meridian Medical 

Technologies, 2555 Hermelin Drive, St. 

Louis, Missouri 63144 applied to be 

registered as an importer of morphine 

(9300), a basic class of controlled 

substance listed in schedule II. 

The company manufactures a product 

containing morphine in the United 

States. The company exports this 

product to customers around the world. 

The company has been asked to ensure 

that its product, which is sold to 

European customers, meets the 

standards established by the European 

Pharmacopeia, administered by the 

Directorate for the Quality of Medicines 

(EDQM). In order to ensure that its 

product will meet European 

specifications, the company seeks to 

import morphine supplied by EDQM for 

use as reference standards. 

This is the sole purpose for which the 

company will be authorized by the DEA 

to import morphine. 

Dated: April 14, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–09343 Filed 4–21–15; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Application: Pharmacore, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.33(a) on 

or before June 22, 2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODXL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.33(a), this is notice that on 

February 4, 2015, Pharmacore, Inc., 

4180 Mendenhall Oaks Parkway, High 

Point, North Carolina 27265, applied to 

be registered as a bulk manufacturer of 

the following basic classes of controlled 

substances: 

Controlled substance Schedule 

Oxymorphine (9652) ..................... II 

Noroxymorphone (9668) .............. II 

The company plans to manufacture 

the listed controlled substance as an 

active pharmaceutical ingredient (API) 

for clinical trials. 

Dated: April 14, 2015. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2015–09334 Filed 4–21–15; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Actavis Laboratories FL, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before May 22, 2015. Such persons 

may also file a written request for a 

hearing on the application pursuant to 

21 CFR 1301.43 on or before May 22, 

2015. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODXL, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Deputy Assistant 

Administrator of the DEA Office of 

Diversion Control (‘‘Deputy Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on 

November 19, 2014, Actavis 

Laboratories FL, Inc., 4955 Orange 

Drive, Davie, Florida 33314 applied to 

be registered as an importer of the 

following basic classes of controlled 

substances: 


asabaliauskas on DSK5VPTVN1PROD with NOTICES